Research on the Mechanism of Prednisone in the Treatment of ITP Via VIP/PACAP-mediated Intestinal Immune Dysfunction

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2023 Feb 8

PMID 36750876

Authors

Xiang Yan

Yayue Zhang

Haiyan Lang

Ziming Huang

Xinyi Chen

Hao He

Qian Zhao

Jun Wang

Affiliations

Soon will be listed here.

Abstract

Rationale: Immune thrombocytopenia (ITP) is thought to be a result of immune dysfunction, which is treated by glucocorticoids such as prednisone. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) have immunomodulatory properties, but their role in intestinal immune control is unclear. The major goal of this study was to look at the effects of prednisone on platelet, VIP, and PACAP levels in ITP mice, as well as the regulatory system that controls intestinal immunity.

Methods: Eighteen BALB/c mice were randomly divided into three groups: blank control group, model control group, and prednisone group, with six mice in each group. The ITP animal model control group and the prednisone group were injected with anti-platelet serum (APS) to replicate the ITP animal model. The prednisone group began prednisone intervention on the 8th day. Platelet count was dynamically measured before APS injection, on the 4th day of injection, on the 1st day of administration, on the 4th day of administration, and at the end of the experiment. After the experiment, the expression of p53 protein in mouse mesenteric lymph node lymphocytes was detected by immunohistochemistry. The changes in lymphocyte apoptosis rate in mouse mesenteric lymph nodes were detected by in situ terminal transferase labeling (TUNEL). The contents of VIP and PACAP in the mouse brain, colon, and serum were detected by enzyme-linked immunosorbent assay (ELISA). The contents of IFN-γ, IL-4, IL-10, IL-17A in the mouse spleen were detected by ELISA.

Results: ①Changes of peripheral platelet count: there was no significant difference in platelet count among the three groups before modeling; on the 4th day, the platelet count decreased in the model control group and prednisone group; on the 8th day, the number of platelets in model control group and prednisone group was at the lowest level; on the 12th day, the platelet count in prednisone group recovered significantly; on the 15th day, the platelet count in prednisone group continued to rise. ②Changes of VIP, PACAP: compared with the blank control group, VIP and PACAP in the model control group decreased significantly in the brain, colon, and serum. Compared with the model control group, the levels of VIP and PACAP in the brain, colon, and serum in the prednisone group were increased except for serum PACAP. ③Changes of mesenteric lymphocytes: the expression of p53 protein in the mesenteric lymph nodes of model control group mice was significantly higher than that of blank control group mice. After prednisone intervention, the expression of p53 protein decreased significantly.④Changes of cytokines in spleen: compared with blank control group, IFN- γ, IL-17A increased and IL-4 and IL-10 decreased in model control group. After prednisone intervention, IFN- γ, IL-17A was down-regulated and IL-4 and IL-10 were upregulated.

Conclusions: Prednisone-upregulated VIP and PACAP levels decreased P53 protein expression and apoptosis rate in mesenteric lymph node lymphocytes and affected cytokine expression in ITP model mice. Therefore, we speculate that the regulation of intestinal immune function may be a potential mechanism of prednisone in treating ITP.

Citing Articles

A novel approach to immune thrombocytopenia intervention: modulating intestinal homeostasis.

Sun H, Yan L, Fang L, Shi Z BMC Immunol. 2024; 25(1):71.

PMID: 39449131 PMC: 11515598. DOI: 10.1186/s12865-024-00660-w.

References

Rincon-Arevalo H, Sanchez-Parra C, Castano D, Yassin L, Vasquez G . Regulatory B Cells and Mechanisms. Int Rev Immunol. 2015; 35(2):156-76. DOI: 10.3109/08830185.2015.1015719. View

Vadnais C, Chen R, Fraszczak J, Hamard P, Manfredi J, Moroy T . A novel regulatory circuit between p53 and GFI1 controls induction of apoptosis in T cells. Sci Rep. 2019; 9(1):6304. PMC: 6474872. DOI: 10.1038/s41598-019-41684-2. View

Harmar A, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna J . Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012; 166(1):4-17. PMC: 3415633. DOI: 10.1111/j.1476-5381.2012.01871.x. View

Zufferey A, Kapur R, Semple J . Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J Clin Med. 2017; 6(2). PMC: 5332920. DOI: 10.3390/jcm6020016. View

Zeng H, Zhao M, Yang S, Huang H, Geng X, Liu J . Vasoactive intestinal peptide alleviates food allergy via restoring regulatory B cell functions. Immunobiology. 2019; 224(6):804-810. DOI: 10.1016/j.imbio.2019.08.006. View

Zhu X, Zhu J . CD4 T Helper Cell Subsets and Related Human Immunological Disorders. Int J Mol Sci. 2020; 21(21). PMC: 7663252. DOI: 10.3390/ijms21218011. View

Audia S, Mahevas M, Samson M, Godeau B, Bonnotte B . Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017; 16(6):620-632. DOI: 10.1016/j.autrev.2017.04.012. View

Sun X, Guo C, Zhao F, Zhu J, Xu Y, Liu Z . Vasoactive intestinal peptide stabilizes intestinal immune homeostasis through maintaining interleukin-10 expression in regulatory B cells. Theranostics. 2019; 9(10):2800-2811. PMC: 6568172. DOI: 10.7150/thno.34414. View

Ding W, Manni M, Stohl L, Zhou X, Wagner J, Granstein R . Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells. Eur J Immunol. 2012; 42(4):901-11. PMC: 3615422. DOI: 10.1002/eji.201141958. View

10.

Delgado M, Ganea D . Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2011; 45(1):25-39. PMC: 3883350. DOI: 10.1007/s00726-011-1184-8. View

11.

Karpiesiuk A, Palus K . Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Physiological and Pathological Processes within the Gastrointestinal Tract: A Review. Int J Mol Sci. 2021; 22(16). PMC: 8395522. DOI: 10.3390/ijms22168682. View

12.

Iwasaki M, Akiba Y, Kaunitz J . Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Res. 2019; 8. PMC: 6743256. DOI: 10.12688/f1000research.18039.1. View

13.

Figueiredo C, Dusedau H, Steffen J, Gupta N, Dunay M, Toth G . Immunomodulatory Effects of the Neuropeptide Pituitary Adenylate Cyclase-Activating Polypeptide in Acute . Front Cell Infect Microbiol. 2019; 9:154. PMC: 6546896. DOI: 10.3389/fcimb.2019.00154. View

14.

Tauschmann M, Prietl B, Treiber G, Gorkiewicz G, Kump P, Hogenauer C . Distribution of CD4(pos) -, CD8(pos) - and regulatory T cells in the upper and lower gastrointestinal tract in healthy young subjects. PLoS One. 2013; 8(11):e80362. PMC: 3827200. DOI: 10.1371/journal.pone.0080362. View

15.

Fu D, Senouthai S, Wang J, You Y . Vasoactive intestinal peptide ameliorates renal injury in a pristane-induced lupus mouse model by modulating Th17/Treg balance. BMC Nephrol. 2019; 20(1):350. PMC: 6728947. DOI: 10.1186/s12882-019-1548-y. View

16.

Neunert C, Terrell D, Arnold D, Buchanan G, Cines D, Cooper N . American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23):3829-3866. PMC: 6963252. DOI: 10.1182/bloodadvances.2019000966. View

17.

Zhang L, Chen K, Li T, He H, Hou L, Wu X . Prednison provokes serum and vasoactive substances in a mice model of immune thrombocytopenia. Iran J Basic Med Sci. 2016; 19(9):1010-1015. PMC: 5080417. View

18.

Kostic M, Zivkovic N, Cvetanovic A, Marjanovic G . CD4 T cell phenotypes in the pathogenesis of immune thrombocytopenia. Cell Immunol. 2020; 351:104096. DOI: 10.1016/j.cellimm.2020.104096. View

19.

Li Q, Liu Y, Wang X, Sun M, Wang L, Wang X . Regulation of Th1/Th2 and Th17/Treg by pDC/mDC imbalance in primary immune thrombocytopenia. Exp Biol Med (Maywood). 2021; 246(15):1688-1697. PMC: 8719040. DOI: 10.1177/15353702211009787. View

20.

Holzer P, Farzi A . Neuropeptides and the microbiota-gut-brain axis. Adv Exp Med Biol. 2014; 817:195-219. PMC: 4359909. DOI: 10.1007/978-1-4939-0897-4_9. View